Molplex Ltd, a Newcastle, UK-based drug discovery company, has raised £350k in funding from the North West Fund for Biomedical.
Led by David Leahy, CEO, Molplex has developed automated decision making systems using predictive chemistry and biology software which incorporate critical decisions made by drug development professionals during the early stages of drug discovery and design.
The company intends to use the capital to progress ten early stage drug projects through laboratory synthesis and testing using its automated systems, complete further updates to the software, as well as establish a base in the North West.
FinSMEs
25/09/2012